The BIRC2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the BIRC2 gene. Derived from the A-549 human lung adenocarcinoma cell line, this product contains a heterogeneous pool of cells with disrupted BIRC2, offering a robust model to investigate apoptosis regulation, NF-??B signaling, and innate immunity. The polyclonal nature minimizes clonal artifacts while preserving the biological complexity of the host cell line.
The A-549 cell line is a well-characterized model of human alveolar type II epithelial cells, widely used in respiratory and oncology research. Originating from a lung adenocarcinoma, these cells exhibit epithelial morphology and retain key features such as surfactant production. A-549 is extensively employed to study lung cancer biology, drug responses, and viral infection, including influenza and SARS-CoV-2. Its genetic stability and relevance to adenocarcinoma make it an ideal host for gene-editing applications, particularly for investigating signaling pathways and chemoresistance mechanisms central to lung cancer.
BIRC2 (cIAP1) encodes an E3 ubiquitin ligase that functions as a critical regulator of apoptosis, NF-??B activation, and innate immune signaling. It ubiquitinates RIPK1 and other substrates downstream of TNFR1, promoting survival complex assembly with TRAF2 and TRAF3. This leads to IKK and NF-??B p65 activation, inducing pro-survival genes such as c-FLIP and Bcl-2. BIRC2 also ubiquitinates caspase-8, inhibiting apoptosis. It interacts with XIAP, SMAC/DIABLO, and NOD2, bridging extrinsic apoptosis and NOD-like receptor pathways. Disruption of BIRC2 sensitizes cells to TNF??-induced death and modulates immune responses.
Within the A-549 lung adenocarcinoma context, BIRC2 knockout sensitizes cells to TNF??-induced apoptosis, offering insights into chemoresistance. A-549 cells harbor a KRAS G12S mutation, a prevalent lung cancer genotype, enabling study of oncogenic and inflammatory crosstalk mediated by TNF??, IL-1??, and TWEAK. Additionally, since A-549 is used for viral infection assays, BIRC2 disruption facilitates examination of its function in antiviral innate immunity through RIG-I and NOD2 pathways. This model thus bridges apoptosis regulation, tumor biology, and host-pathogen interactions.
This knockout model supports a range of experiments, including western blotting for cleaved caspase-3 and I??B??, annexin V/PI apoptosis assays, NF-??B luciferase reporter assays, co-immunoprecipitation of RIPK1/TRAF2, and RT-qPCR of NF-??B target genes. TNF??/CHX viability tests and chemosensitivity screening with cisplatin or pemetrexed further reveal chemoresistance profiles. The BIRC2 Knockout A-549 Polyclonal Cells thus provide a robust platform for apoptosis, NF-??B, and drug development studies. For further research or collaboration inquiries, please contact Ascent Research.
